Effect of calcium carbonate D3 tablets combined with leuprorelin on sex hormones and bone metabolism in girls with central precocious puberty

doi:10.3877/cma.j.issn.1674-0785.2022.10.008

Abstract

Abstract:

Objective

To explore the effect of calcium carbonate D3 tablets combined with leuprorelin on sex hormones and bone metabolism in girls with central precocious puberty (CPP).

Methods

A total of 146 girls with precocious puberty who visited Wuxi Children's Hospital from January 2019 to January 2021 were included in this study and divided into either a control group or a study group. The control group was treated with leuprorelin alone, and the study group was given leuprorelin plus calcium carbonate D3 tablets. Growth index, sex hormone levels, sex gland volume, and bone metabolism were compared between the two groups.

Results

The 12-month growth rate (GV) and predicted adult height (PAH) in the study group were significantly higher than those in the control group (P＜0.05). Peak follitropin beta (PFSH) , lutropin alpha (PLH), and estradiol (E2) in the study group were signifiancely lower than those in the control group at 3 months after treatment (P＜0.05). Ovarian volume, uterine volume, and follicle diameter in the study group were significantly lower than those of the control group after 12 months of treatment (P＜0.05). Blood calcium (Ca) and vitamin D [25-(OH)] were significantly higher and osteocalcin (Ost) and type I collagen carboxyl terminal peptide (β-CTX) were significantly higher in the study group than in the control group (P＜0.05) after 12 months of treatment. The total incidence of adverse reactions did not differ significantly between the study group and the control group (8.22% vs 6.85%, respectively, P＞0.05).

Conclusion

Calcium carbonate D3 tablets combined with leuprorelin can effectively improve the growth and development of CPP girls, inhibit the development of the gonads, and help regulate bone metabolism.

Key words: Precocious puberty, Calcium carbonate D3 tablets, Calcium, Gonadal volume, Bone metabolism

Xiping Wang, Xu Xu, Li Jiang, Lulian Xu, Kefeng Gu, Zhenzhen Liu, Yang Lu. Effect of calcium carbonate D3 tablets combined with leuprorelin on sex hormones and bone metabolism in girls with central precocious puberty[J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(10): 965-969.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2022.10.008

https://zhlcyszz.cma-cmc.com.cn/EN/Y2022/V16/I10/965

Figures/Tables 5

References 20

1	Fernandes Júnior GA, Silva DA, Mota LFM, et al. Sustainable intensification of beef production in the tropics: the role of genetically improving sexual precocity of heifers [J]. Animals (Basel), 2022, 12(2): 174.
2	Shan C, Yue J, Liu W. Broadening the role of osteocalcin in the hypothalamic-pituitary-gonadal axis [J]. J Endocrinol, 2021, 249(2): R43-R51.
3	林园园, 徐婷婷. 不同剂量重组人生长激素治疗女性中枢性性早熟患儿的效果及对雌激素水平和发育指标的影响 [J]. 中国妇幼保健, 2021, 36(18): 4261-4264.
4	Gonc EN, Kandemir N. Body composition in sexual precocity [J]. Curr Opin Endocrinol Diabetes Obes, 2022, 29(1): 78-83.
5	De Sanctis V, Soliman AT, Di Maio S, et al. Long-term effects and significant adverse drug reactions (ADRs) associated with the use of gonadotropin-releasing hormone analogs (GnRHa) for central precocious puberty: a brief review of literature [J]. Acta Biomed, 2019, 90(3): 345-359.
6	中华医学会儿科学分会内分泌遗传代谢学组. 中枢性性早熟诊断与治疗共识 [J]. 中华儿科杂志, 2015, 53(6): 412-418.
7	Heras V, Castellano JM, Fernandois D, et al. Central ceramide signaling mediates obesity-induced precocious puberty [J]. Cell Metab, 2020, 32(6): 951-966.
8	Wang C, Chen Q, Yuan K, et al. The first central precocious puberty proteomic profiles revealed multiple metabolic networks and novel key disease-associated proteins [J]. Aging (Albany NY), 2021, 13(21): 24236-24250.
9	Gohil A, Eugster EA. Delayed and precocious puberty: genetic underpinnings and treatments [J]. Endocrinol Metab Clin North Am, 2020, 49(4): 741-757.
10	Neocleous V, Fanis P, Toumba M, et al. Pathogenic and low-frequency variants in children with central precocious puberty [J]. Front Endocrinol (Lausanne), 2021, 12: 745048.
11	El-Sharkawy A, Malki A. Vitamin D signaling in inflammation and cancer: molecular mechanisms and therapeutic implications [J]. Molecules, 2020, 25(14): 3219.
12	Maqdasy S, Barres B, Salaun G, et al. Idiopathic central precocious puberty in a Klinefelter patient: highlights on gonadotropin levels and pathophysiology [J]. Basic Clin Androl, 2020, 30(1): 19.
13	孙志豪, 吴东明, 张荣华. 维生素D对促性腺激素释放激素类似物治疗中枢性性早熟的研究 [J]. 河北医药, 2020, 42(8): 1160-1164.
14	余月, 刘德云, 杨琍琦, 等. 特发性中枢性性早熟女童糖脂代谢指标,维生素D和性激素水平分析 [J]. 实用医学杂志, 2020, 36(22): 3079-3083.
15	Silva MSB, Giacobini P. New insights into anti-Mullerian hormone role in the hypothalamic-pituitary-gonadal axis and neuroendocrine development [J]. Cell Mol Life Sci, 2021, 78(1): 1-16.
16	Assirelli V, Baronio F, Ortolano R,et al. Transient central precocious puberty: a new entity among the spectrum of precocious puberty? [J]. Ital J Pediatr, 2021, 47(1):210.
17	Aguirre RS, Eugster EA. Central precocious puberty: from genetics to treatment [J]. Best Pract Res Clin Endocrinol Metab, 2018, 32(4): 343-354.
18	杨永红, 鲁力, 夏凤琼, 等. 老年血清骨代谢物骨钙素,Ⅰ型胶原C端肽,骨源性碱性磷酸酶与骨密度的相关性 [J]. 中国老年学杂志, 2016, 36(20): 5112-5113.
19	林晓悦, 蔡树玉, 刘文刚, 等. 血清25羟维生素D与2型糖尿病男性患者勃起功能障碍的相关性分析 [J]. 临床内科杂志, 2021, 38(4): 236-239.
20	Al-Agha AE, Mabkhoot YM, Bahwirith AS, et al. Various causative factors and associated complications of childhood obesity in Jeddah, Western Region, Saudi Arabia [J]. Ann Afr Med, 2020, 19(1): 15-19.

组别	例数	BA		PAH（cm）		GV（cm/年）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	73	7.79±1.06	7.85±1.03^a	140.84±4.05	152.34±1.73^a	4.67±0.44	5.14±0.53^a
研究组	73	7.84±1.10	7.94±1.11^a	142.12±3.98	156.27±2.12^a	4.69±0.54	6.28±0.61^a
t值		0.280	0.508	1.926	12.271	0.245	12.053
P值		0.780	0.612	0.056	＜0.001	0.807	＜0.001

组别	例数	BA		PAH（cm）		GV（cm/年）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	73	7.79±1.06	7.85±1.03^a	140.84±4.05	152.34±1.73^a	4.67±0.44	5.14±0.53^a
研究组	73	7.84±1.10	7.94±1.11^a	142.12±3.98	156.27±2.12^a	4.69±0.54	6.28±0.61^a
t值		0.280	0.508	1.926	12.271	0.245	12.053
P值		0.780	0.612	0.056	＜0.001	0.807	＜0.001

组别	例数	PFSH（IU/l）		PLH（IU/l）		E₂（pg/ml）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	73	17.86±1.54	4.36±0.50^a	19.32±1.37	2.77±0.20^a	32.86±2.64	16.19±1.05^a
研究组	73	17.79±1.58	4.13±0.45^a	19.26±1.35	2.67±0.18^a	32.75±2.58	14.27±1.07^a
t值		0.271	2.921	0.267	3.175	0.255	10.943
P值		0.787	0.004	0.790	0.002	0.799	＜0.001

组别	例数	PFSH（IU/l）		PLH（IU/l）		E₂（pg/ml）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	73	17.86±1.54	4.36±0.50^a	19.32±1.37	2.77±0.20^a	32.86±2.64	16.19±1.05^a
研究组	73	17.79±1.58	4.13±0.45^a	19.26±1.35	2.67±0.18^a	32.75±2.58	14.27±1.07^a
t值		0.271	2.921	0.267	3.175	0.255	10.943
P值		0.787	0.004	0.790	0.002	0.799	＜0.001

组别	例数	卵巢容积（ml）		子宫容积（ml）		卵泡直径（mm）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	73	2.89±0.66	1.87±0.51^a	3.11±0.67	1.81±0.41^a	6.77±1.06	3.78±0.89^a
研究组	73	2.93±0.69	1.14±0.17^a	3.02±0.71	1.53±0.26^a	6.85±0.96	3.24±0.62^a
t值		0.358	11.602	0.788	4.928	0.478	4.254
P值		0.721	＜0.001	0.432	＜0.001	0.633	＜0.001

Please choose a citation manager

Content to export